echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Top 10 cases in the field of antibody drugs in 2017: involving about 4.433 billion yuan

    Top 10 cases in the field of antibody drugs in 2017: involving about 4.433 billion yuan

    • Last Update: 2018-02-08
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Source: huoshichuang 2018-02-08 public data of huoshichuang collation shows that in 2017, there were 19 financing cases in the field of antibody drugs in China, involving a total amount of 4.692 billion yuan, accounting for 51.35% and 73.11% of the total financing in the field of biological drugs respectively Among them, the financing amount of top 10 enterprises is about 4.433 billion yuan Due to the development of biotechnology, the maturity of antibody coupling technology and the vigorous development of cro enterprises in China, the R & D cycle of biopharmaceuticals has been greatly shortened, which makes biopharmaceuticals develop rapidly Antibody drugs account for about 40% of the market share of biotechnology drugs, and the market share continues to grow It can be said that all of the world's top 50 pharmaceutical enterprises do antibody At the same time, the capital market also pays close attention to the development of antibody drugs According to the open data of Huoshi creation, 19 financing cases occurred in the field of antibody drugs in 2017, involving a total amount of 4.692 billion yuan, accounting for 51.35% and 73.11% of the total financing in the field of biological drugs respectively In the technical subdivision of antibody drugs, the investment in the field of monoclonal antibodies accounted for the main body, with 15 financing cases involving 3.423 billion yuan, accounting for 78.95% and 72.95% of the total financing in the field of antibody drugs, respectively Below, the author will give a brief introduction to the top 10 enterprises in the field of antibody drugs that obtained financing in 2017 according to the amount of financing Rongchang Pharmaceutical Co., Ltd of Yantai Rongchang Pharmaceutical Co., Ltd has developed into a modern pharmaceutical enterprise integrating R & D, production, sales and service, covering four major fields: Modern Chinese medicine, biopharmaceutical, biopharmaceutical R & D and production outsourcing, Biopharmaceutical Enterprises and project incubation In the field of antibody drugs, rc48 developed by Rongchang pharmaceutical for the treatment of gastric cancer, breast cancer and other cancer diseases has obtained the clinical approval issued by the State Food and drug administration It is the first ADC drug to enter human clinical trials in China, marking a breakthrough in the field of ADC drug research and development in China In addition, as early as 1997, Rongchang pharmaceutical, as the first domestic enterprise to enter the field of biological new drug creation, has successfully developed a new type of biological new drug recombinant human endostatin (trade name: endu) The listing of the drug marks that China's research and development of anti-tumor drugs of vascular inhibitors has been in the forefront of the world In December 2017, Rongchang pharmaceutical obtained a strategic financing of RMB 1 billion from Shenzhen Venture Capital, Guotou venture capital, PAG taimeng investment group, Longpan investment, Guotou hi tech leading investment, Huatai Securities, Jifu venture capital, Zhongguo venture capital, Luxin venture capital, Zhongtai Huiyin investment Tianjing bio Tianjing bio was founded in 2014 It is a new biological drug R & D company focusing on tumor immunity and autoimmune disease treatment In June 2016, it obtained a round of financing led by Jianqiao capital Founded in 2015, tianshizhen biotechnology is jointly invested and established by Jianqiao capital, Shanghai Tianshili Pharmaceutical Co., Ltd and genexine Inc., an overseas biotechnology company Its business scope mainly covers the development of drugs for diabetes, tumor and autoimmune diseases On March 21, 2017, Sanjing biology and tianshizhen biology merged into Tianjing biology, and obtained round B financing led by Kangqiao capital and Shanghai Tianshili pharmaceutical industry Based in China, Tianjing bio develops innovative antibody drugs for the world The R & D team has more than 15 years of experience in R & D management of multinational and local pharmaceutical enterprises on average It has strong strength in early R & D, antibody molecular engineering, target discovery and verification, antibody process development and pre clinical evaluation, quality science and management, clinical research and other fields The R & D pipeline of Tianjing biology is divided into two project sets, with a total of 12 projects under research, which are respectively for global R & D and clinical R & D in China In March 2017, Tianjing bio obtained the B round financing of 150 million US dollars invested by Kangqiao capital and Tianshili health industry fund Thinking: 3D medicine focuses on the precise medical treatment of tumor By integrating and mining the biological characteristics of tumor, clinical diagnosis and treatment and drug research and development data, it carries out the three in one business model of early tumor screening, precise diagnosis of tumor and precise drug research and development, and becomes a Chinese practitioner of the integration of tumor diagnosis and treatment Founded in 2010, the company cooperates with more than 200 top three hospitals in China to provide comprehensive integrated tumor diagnosis and treatment products and services (covering saliva, tumor tissue and blood source sample testing) for different groups of people The company's R & D pipeline of new anti-tumor drugs covers immunotherapy and other targeted therapies At present, it is the world's first new anti-PD-L1 tumor immunotherapy project under the cooperation of the company In November 2017, thinkti obtained strategic financing of RMB 67000000 from state-owned capital investment fund and China trust capital investment The figure shows the development of new drug research and development of thinkti (source: official website) Yianjishi was initially founded in Seattle, USA by four senior experts of Amgen, and its Chinese joint venture Hangzhou yianjishi biopharmaceutical Co., Ltd was founded in February 2016 Yianjishi is committed to explore the field of monoclonal antibody biological medicine treatment, and solve or eliminate a series of technical obstacles in the early and efficient development of antibody by means of the comprehensive design from gene drug molecules to process development to production plant At present, yianjishi has a complete clinical development and production system, and several new products will enter the international clinical stage in 2018 Up to now, Yian Jishi has completed three rounds of financing, as shown in the table below: Frontier biopharmaceutical (Nanjing) Co., Ltd frontier biopharmaceutical is an innovative biopharmaceutical enterprise based in China and facing the global market At this stage, we focus on the R & D and promotion of innovative drugs in important treatment fields such as anti-virus treatment of AIDS and pain Frontier biology has a long-term peptide drug R & D platform with global intellectual property rights and a number of products under research The monoclonal antibody 3bnc117 in the company's product line is a broad-spectrum neutralizing HIV antibody from all human sources Its target is the CD4 binding site above the HIV-1 membrane protein gp120 It is one of the widespectrum neutralizing HIV antibodies with the best efficacy and the fastest clinical progress in the world It has completed a number of phase I and phase II clinical trials in the United States The preclinical and clinical data indicate that 3bnc117 is safe, has certain anti retroviral activity, can inhibit the replication of HIV virus, and can induce immune response and clear the infected cells In January 2017, cutting edge biology obtained RMB 300 million c-round financing jointly funded by Huaxin century leading investment, Shenzhen Venture Capital and Yifeng venture capital Kangfang bio Pharmaceutical Co., Ltd is an innovative bio pharmaceutical company headquartered in the national health industry base of Torch Development Zone, Zhongshan City, Guangdong Province It is committed to the discovery and development of innovative antibody drugs with independent intellectual property rights In December 2015, kangfangbio sold ak-107, a monoclonal antibody for tumor immunotherapy, to MSD in the US for us $200 million, and became famous overnight In October 2017, kangfang biology announced that ak101 injection, the company's new anti-IL-12 / IL-23 McAb drug, obtained the approval document for clinical trial issued by the State Food and Drug Administration (CFDA) on September 27, and the first phase of clinical trial will be carried out soon Ak101 antibody drug is independently developed by kangfang biology, with full independent intellectual property rights and global development rights It is the first anti-IL-12 / IL-23 monoclonal antibody injection in China to independently innovate and obtain clinical trial approval In August 2017, kangfang bio obtained a round B financing of RMB 300 million from gaotejia leading investment, Qianhai master fund, Shenzhen Venture Capital and Qinzhi capital Beijing tianguangshi Biotechnology Co., Ltd tianguangshi is a biopharmaceutical company in the clinical stage It has the domestic leading technical ability of monoclonal antibody research and development and industrialization and has formed a perfect technical system The company has grown into a high-tech company with a perfect technical system of anti-body drug development and industrialization The company's technology platform includes fucose knockout technology platform, dual function antibody technology platform, ADC R & D technology platform, antibody discovery and screening technology platform, antibody activity identification and screening technology platform, serum-free chemical composition determination medium platform, etc The analogues of mil60 bevacizumab is an antibody drug developed by tianguangshi At present, its clinical research on the treatment of non-small cell lung cancer has entered phase III Mil77 is an antibody for Ebola, and it has entered phase I clinical practice Tianguangshi's drug research and development in the clinical stage in January 2017, tianguangshi obtained the leading investment of gaotejia investment, followed by 270 million RMB round B financing invested by Jiashi investment, power capital and Yizhuang pharmaceutical M & A fund Beijing Yiqiao Shenzhou Technology Co., Ltd Yiqiao Shenzhou was founded in 2007, focusing on the research, development and production of recombinant protein, antibody and ELISA kit Products are mainly used in immunology, cell biology, tumor, neurobiology, stem cells, viruses and other related fields of life science research and drug development At the same time, the company is also committed to research, development and technical services of biotechnology drugs, such as monoclonal antibodies, recombinant protein drugs, virus vaccines, rapid diagnosis, etc   Yiqiao Shenzhou has a leading production technology platform for monoclonal antibodies and recombinant protein drugs It has provided pre clinical production technology services for hundreds of monoclonal antibody candidate drugs for well-known pharmaceutical enterprises and biotechnology companies It takes only a few weeks from gene sequence to 1-30g purified monoclonal antibody It is the fastest antibody production enterprise in the world One On July 6, 2017, Yiqiao Shenzhou obtained the round a financing of RMB 200 million led by Qiming venture capital An Mai biological an Mai biological a new biopharmaceutical innovative R & D company, product development is mainly focused on the field of cancer, the main business is bispecific antibody research and development Its independently developed fit Ig (Fabs in tandem immunity) technology is a unique and efficient innovative platform technology for developing bispecific antibody products In June 2016, Anmai biology and Suzhou Xinda biopharmaceutical Co., Ltd reached an agreement on authorization and cooperation of bispecific antibody technology The cooperation gave full play to fit Ig's unique platform technology, and rapidly pushed more products to the clinical development stage In April 2017, Anmai biology announced the completion of round a financing of US $25 million Through this round of financing, Anmai biology will further promote its self-developed bispecific antibody research and development platform and build the development pipeline of therapeutic antibody drugs for tumor immunity and other related fields Kangnaide biopharmaceutical kangnaide biopharmaceutical is a new drug innovation company with global rights and interests in clinical products, focusing on the discovery and development of new immunomodulators to treat autoimmune diseases and inflammation Its unique R & D technology platform based on the biological function of T cells helps kangnaide to effectively obtain new drug molecules targeting the clinically proven disease pathway targets The main candidate drug cbp-307 is a new generation of oral S1P1 and S1P5 (GPCR) modulators, which can treat many autoimmune diseases, including inflammatory bowel disease, psoriasis, multiple sclerosis, etc Second
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.